within Pharmacolibrary.Drugs.C_CardiovascularSystem.C03A_LowCeilingDiureticsThiazides.C03AA03_Hydrochlorothiazide;

model Hydrochlorothiazide
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.65,
    Cl = 1.8166666666666665e-06,
    adminDuration = 600,
    adminMass = 25 / 1000000,
    adminCount = 1,
    Vd = 0.0036,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.012166666666666666,
    Tlag = 9.0);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Hydrochlorothiazide</td></tr><tr><td>ATC code:</td><td>C03AA03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>25</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>109</td><td>ml/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Hydrochlorothiazide is a thiazide diuretic commonly used to treat hypertension, edema associated with congestive heart failure, liver cirrhosis, and chronic kidney disease. It reduces blood pressure by promoting the excretion of sodium and water in the kidneys. Hydrochlorothiazide is widely approved and used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adults following oral administration.</p><h4>References</h4><ol><li><p>Van Wart, SA, et al., &amp; Mager, DE (2013). Population-based meta-analysis of hydrochlorothiazide pharmacokinetics. <i>Biopharmaceutics &amp; drug disposition</i> 34(9) 527–539. DOI:<a href=\"https://doi.org/10.1002/bdd.1863\">10.1002/bdd.1863</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24123104/\">https://pubmed.ncbi.nlm.nih.gov/24123104</a></p></li><li><p>Ngo, L, et al., &amp; Lee, YB (2018). Effects of hydrochlorothiazide and amlodipine on single oral dose pharmacokinetics of valsartan in healthy Korean subjects: Population model-based approach. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 118 154–164. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2018.03.031\">10.1016/j.ejps.2018.03.031</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/29604332/\">https://pubmed.ncbi.nlm.nih.gov/29604332</a></p></li><li><p>Kousovista, R, et al., &amp; Karalis, V (2021). Validation of population pharmacokinetic models: a comparison of internal and external validation approaches for hydrochlorothiazide. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 51(12) 1372–1388. DOI:<a href=\"https://doi.org/10.1080/00498254.2021.2012727\">10.1080/00498254.2021.2012727</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34842039/\">https://pubmed.ncbi.nlm.nih.gov/34842039</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C03AA03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Hydrochlorothiazide;
